1,4-diazabicylo[3,2,2]nonane derivatives, their preparation and their therapeutic application

• US 6,407,095 B1
• Filed: 07/16/2001
• Issued: 06/18/2002
• Est. Priority Date: 12/04/1998
• Status: Expired due to Term

• Current Assignee: Sanofi
• Original Assignee: Sanofi-Synthelabo Incorporated (Sanofi-Aventis U.S., LLC)
• Inventors: Even, Luc, Lochead, Alistair, Jegham, Samir, Jeunesse, Jean, Nedelec, Alain, Galli, Frédéric
• Primary Examiner(s): Raymond, Richard L.
• Assistant Examiner(s): Balasubramanian, Venkataraman
• Application Number:
  US09/856,945
• Time in Patent Office: 337 Days
• Field of Search: 540/567, 514/221
• US Class Current: 514/221
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: C07D 471/08 Bridged systems

Abstract

The invention relates to 1,4-diazabicyclo[3.2.2]nonane derivatives, to pharmaceutical compositions containing them, and to methods for the treatment or prevention of disorders associated with a dysfunction of the nicotinic receptors utilizing them.

Claims

1. A compound of general formula (I)

in which

one of the symbols X, Y and Z represents a nitrogen atom, another represents a group of formula C—

R₃ and the third represents a nitrogen atom or a group of formula C—

R₄,

R₃ and R₄ represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxyl, (C₁-C₆)alkyl or (C₁-C₆)alkoxy group,

R₁ and R₂ represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxyl, (C₁-C₆)alkyl or (C₁-C₆)alkoxy group or a phenyl group optionally substituted with a halogen atom, with a trifluoromethyl group, with a cyano group, with a nitro group, with a hydroxyl group, with a (C₁-C₆)alkyl group, with a (C₁-C₆)alkoxy group, with an acetyl group, with a methylenedioxy group, with a trifluoromethoxy group, with a methylthio group or with a phenyl group, in the form of a base or of an addition salt with an acid.

2. A compound according to claim 1 wherein the heterocycle containing X, Y and Z is a 3-pyridyl group.

3. A compound according to claim 1 wherein the heterocycle containing X, Y and Z is a 3-pyridazinyl group.

4. A method for the treatment of disorders associated with a dysfunction of the nicotinic receptors which comprises administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1 to 3.

5. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 3 together with an excipient.